Los Angeles–based Kythera Biopharmaceuticals, a developer of aesthetic medicine products, has raised $37.4 million in a series D round of venture capital financing. The new investors in the investment round include Foley Ventures and Latham and Watkins. Existing investors, including Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco, and Altitude Life Science Ventures took part in the fundraising round. The new investment brings the total raised amount to more than $108 million.
Click here for the release from Business Wire.